The Only FDA-Approved CBD Treatment For Severe Epilepsy Completes Key Phase 3 Trial In Japan Despite Missed Primary Goal - Jazz Pharmaceuticals ( NASDAQ:JAZZ )

4 weeks ago

Jazz Pharmaceuticals JAZZ reported results from a Phase 3 trial in Japan evaluating the safety and efficacy of cannabidiol oral solution, Epidiolex, for treating seizures in children with rare forms of epilepsy, such as Lennox-Gastaut syndrome, Dravet syndrome and tuberous sclerosis complex.

Ticker	Sentiment	Impact
JAZZ	Neutral	45 %